Efficacy and Safety of SQV in Patients Who Have Chronic IDV Nephrotoxicity

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Efficacy and safety of a saquinavir (SQV) based regimen in HIV-1 infected Thai patients who have chronic indinavir (IDV) associated nephrotoxicity.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
• Collaborators: Ministry of Health, Thailand; Roche Pharma AG
• Treatments: Saquinavir

Criteria

Inclusion Criteria:

• IDV containing regimen for more than 1 year and have creatinine more than 1.4 at least 6 months/abnormal renal imaging/abnormal urinary examinations

• Viral load less than 50 copies

Exclusion Criteria:

• Saquinavir intolerance